In building and developing our portfolio, we are guided by three overarching principles. The therapeutic target or pathway for each program is genetically linked to neurodegenerative disease. Our product candidates are engineered to optimize brain delivery. The clinical development plan is enabled by biomarkers. We rigorously follow the science and employ the therapeutic modality that we believe is best suited to modulate the target pathway.